Epigenomics Seeks Diagnostic Partner to Market Prostate Cancer Array Test

Berlin-based Epigenomics is keen to license the assay, which relies on profiling DNA methylation of the gene PITX2, to a diagnostic partner for commercialization.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.